Will Minerva Neurosciences stock go up?

According to Danelfin AI, Minerva Neurosciences has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (46.00%) is -4.82% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Minerva Neurosciences stock?

The Minerva Neurosciences target price is $5.12 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Minerva Neurosciences stock right now?

Minerva Neurosciences has today a Sell rating (AI Score 3/10), according to Danelfin AI. Its probability of beating the market in 3 months (46.00%) is -4.82% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Minerva Neurosciences stock is a good buy .

Is Minerva Neurosciences undervalued right now?

Based on analysts, the average price target downside for Minerva Neurosciences is 0.00% (1Y). According to Danelfin AI, Minerva Neurosciences has today an AI Score of 3/10 (Sell Rating).

What was the price range of Minerva Neurosciences stock over the past 12 months?

The Minerva Neurosciences stock price range over the past 12 months has been $1.63 - $8.07.

What is going on with Minerva Neurosciences stock in the last 3 months?

The Minerva Neurosciences stock performance in the last quarter has been -8.57%.

Does Minerva Neurosciences offer dividend payments?

No, Minerva Neurosciences does not currently pay dividends.

What is the current market capitalization of Minerva Neurosciences?

Minerva Neurosciences's market cap is $237.6M, as of 2026-07-03 08:00.

Minerva Neurosciences Inc (NERV) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

NERV AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Size & Liquidity+0.50%
Company size and trading liquidity
Growth+0.34%
Expected pace of revenue and earnings expansion
Sentiment+0.14%
How analysts and the market view the stock

Volatility-2.18%
How much the stock price tends to fluctuate
Momentum-2.05%
Direction and strength of recent price movements
Valuation-0.80%
How the stock is priced relative to its fundamentals
Financial Strength-0.43%
Balance sheet strength and financial resilience
Earnings Quality-0.35%
Stability and reliability of reported earnings

NERV probability advantage of beating the market (3M):

-4.82%

AI Score

Sell

Minerva Neurosciences (NERV) has an AI Score of 3/10 (Sell) because, according to an overall analysis, it has a probability advantage of -4.82% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of NERV (46.00%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
NERV probability advantage of beating the market (3M)-4.82%
NERV probability of beating the market (3M)46.00%

NERV probability advantage of beating the market (3M): -4.82%

The AI-powered overall analysis of Minerva Neurosciences (NERV) is based on the 28 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of NERV:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Income (TTM)	-$415.07M	N/A	+2.78%
Technical	Chart Pattern (120d)	figure_33	N/A	-2.19%
Technical	Maximum Volatility	9.78%		-1.58%
Technical	Chart Pattern (504d)	figure_42	N/A	-1.40%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.27%
Technical	Performance (YTD)	0.27%		-1.19%
Technical	Normalized Average True Range (50d)	9.28%		-1.00%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.90%
Technical	Alpha 1Y	1.86%		+0.70%
Sentiment	Industry (GICS)	Biotechnology	N/A	+0.69%
Technical	Upgrade to unlock			-0.66%
Technical	Upgrade to unlock			-0.63%
Sentiment	Upgrade to unlock			+0.60%
Technical	Upgrade to unlock			+0.54%
Fundamental	Upgrade to unlock			-0.51%

Rest of Alpha Signals: -0.60%

NERV probability advantage of beating the market (3M)Total:-4.82%
NERV AI Score

Significant changes Vs previous day

NERV Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$5.12
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

NERV Proven Sell Signal & Price Forecast

This is the price chart for NERV from January 2, 2026 until today. The chart indicates, in red, the 75 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

NERV Average Past Performance & Loss Rate

Three months after its 1101 Sell signals since July 2026, NERV had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

1101 Past NERV Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-21.39%
Average Alpha				-36.62%
Loss Rate (% Negative Perf.)				80.73%
% Negative Alpha				85.77%

NERV Frequently Asked Questions

Will Minerva Neurosciences stock go up?
According to Danelfin AI, Minerva Neurosciences has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (46.00%) is -4.82% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Minerva Neurosciences stock?
Is it a good time to buy, sell, or hold Minerva Neurosciences stock right now?
Is Minerva Neurosciences undervalued right now?
What was the price range of Minerva Neurosciences stock over the past 12 months?
What is going on with Minerva Neurosciences stock in the last 3 months?
Does Minerva Neurosciences offer dividend payments?
What is the current market capitalization of Minerva Neurosciences?

Minerva Neurosciences Inc Company Profile

As a clinical-stage biopharmaceutical establishment, Minerva Neurosciences, Inc. operates with a core focus on the creation and market introduction of advanced therapeutic solutions aimed at treating central nervous system diseases. Key among its product line is the distinguished roluperidone (also known as MIN-101), a groundbreaking pharmaceutical candidate curated for addressing negative symptoms in those diagnosed with schizophrenia--and presently in the process of obtaining a New Drug Application certification.

Additionally, it developed MIN-301, an innovative formulation of the neuregulin-1b1 protein in soluble recombinant form. This curative substance represents a beacon of hope for patients battling Parkinson's disease and other similar neurodegenerative disorders. For its operations beyond the borders of Asia, Minerva Neurosciences, Inc. has secured an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation that allows them to further research, market and import roluperidone globally.

Having its genesis back in 2007, this promising enterprise establishes its operational base in Burlington, Massachusetts. Rooted firmly in highly specialized neuroscience research and innovation, the company persists on its mission to bring life-changing treatments to patients grappling with complex neurological conditions.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:1601 Trapelo Road, Suite 284, Waltham
Employees:7
Website:minervaneurosciences.com

Pros

High patient switching costs for effective CNS treatments

Intellectual property protection for successful drug compounds

Addressing substantial unmet medical needs in CNS disorders

Potential for market exclusivity via orphan drug status

Extensive regulatory and development barriers to entry

Cons

Substantial capital requirements for drug research and development

High risk of clinical trial failure for drug candidates

Protracted and uncertain drug regulatory approval processes

Concentrated pipeline risk with few advanced drug assets

Payer reimbursement and drug pricing negotiation challenges

Company	AI Score	Compare
NBIXNeurocrine Biosciences Inc
NMRANeumora Therapeutics Inc
SUPNSupernus Pharmaceuticals Inc
RLMDRelmada Therapeutics Inc

Company	AI Score	Compare
NBIXNeurocrine Biosciences Inc
NMRANeumora Therapeutics Inc
SUPNSupernus Pharmaceuticals Inc
RLMDRelmada Therapeutics Inc

NERV Stock AI Analysis